DHR
DanaherDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Earnings surprise screen
86High quality2026-07-21 bmo
Danaher combines a positive +0.62% Earnings ESP, consensus Q2 revenue of approximately $6.09 billion, management commentary on a recovery led by bioprocessing and Life Sciences, strong pre-event price action, a 0.95 close-location reading, and relative strength versus XLV; the main caution is disclosed shareholder litigation and only modest revenue growth.
Revision
24
Revenue
11
Business
17
Price
18
Volume
8
Risk
8
Required signals: None marked positive
Preferred signals: None marked positive
Risk flags: Complete prior EPS and revenue beat-streak verification was not established., No reliable pre-event analyst-bearishness measure was found.
Screen as of 2026-07-17. Window 2026-07-17 to 2026-07-23.
Setup hits (3d)
Net Neutral
0 setup hits in the last 3 trading days, 0 bullish, 0 bearish, net strength weak.
Review the highest-weight setup hits and confirm with price action before acting.
Total Hits
0
Last 3d
Bullish
0
0% of hits
Bearish
0
0% of hits
Net Bias
Net Neutral
Balanced
Top Strength
weak
Weighted strength
Bullish setup hits
Sorted by strength
No setup hits found in the last 3 trading days.
Recent setup history
Date
Bullish
Bearish
Total
7.18
Latest
0
0
0
7.17
1d ago
0
0
0
7.16
2d ago
0
0
0
Bullish hitBearish hit- No activity
Open full setup hits view
Setup hits are derived from RankAlpha screener rules firing within the last 3 trading days. Net bias reflects the weighted balance of bullish vs bearish hits.